TIGIT inhib 
Welcome,         Profile    Billing    Logout  
 17 Companies  17 Products   17 Products   0 Diseases   74 Trials   570 News 
241 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tiragolumab (RG6058) / Roche
SKYSCRAPER-02, NCT04256421 / 2019-003301-97: A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Checkmark From SKYSCRAPER-02 trial in combination with or without tiragolumab for ES SCLC
Mar 2022 - Mar 2022: From SKYSCRAPER-02 trial in combination with or without tiragolumab for ES SCLC
Active, not recruiting
3
490
Europe, Japan, US, RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Carboplatin, Etoposide, Placebo
Hoffmann-La Roche
Small Cell Lung Cancer
09/22
05/25
SKYSCRAPER-08, NCT04540211: A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

Jan 2023 - Dec 2023: Data from SKYSCRAPER-08 trial in combination with tiragolumab for metastatic esophageal carcinoma
Active, not recruiting
3
461
RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Paclitaxel, Cisplatin, Atezolizumab Matching Placebo, Tiragolumab Matching Placebo
Hoffmann-La Roche
Esophageal Cancer
02/23
01/26
SKYSCAPPER-02C, NCT04665856: Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Active, not recruiting
3
123
RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Carboplatin, Etoposide, Tiragolumab Matching Placebo
Hoffmann-La Roche
Small Cell Lung Carcinoma
08/23
12/25
SKYSCRAPER-15, NCT06267001: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Active, not recruiting
3
56
Europe, Japan, RoW
Atezolizumab, Tecentriq; RO5541267, Tiragolumab, MTIG7192A; RO7092284, Placebo
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
12/25
12/25
SKYSCRAPER-03, NCT04513925 / 2019-004773-29: A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Calendar Jan 2025 - Dec 2025: From SKYSCRAPER-03 trial in combination with Tecentriq for unresectable stage 3 NSCLC
Active, not recruiting
3
829
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq; RO5541267, Tiragolumab, MTIG7192A; RO7092284, Durvalumab
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
08/25
12/27
SKYSCRAPER-01, NCT04294810 / 2019-002925-31: A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Jul 2023 - Sep 2023: Final analysis data from SKYSCRAPER-01 trial in combination with tiragolumab for NSCLC
Jan 2023 - Feb 2023: Interim data from SKYSCRAPER-01 trial in combination with tiragolumab for NSCLC
Checkmark Interim results from SKYSCRAPER-01 trial in combination with Tecentriq for 1L NSCLC
Jul 2022 - May 2022: Interim results from SKYSCRAPER-01 trial in combination with Tecentriq for 1L NSCLC
Active, not recruiting
3
620
Europe, Japan, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Matching Placebo
Hoffmann-La Roche
Non-Small Cell Lung Cancer
09/24
12/25
Imbrave 152, NCT05904886: A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Tiragolumab, MTIG7192A, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical
Carcinoma, Hepatocellular
09/26
09/26
SKYSCRAPER-07, NCT04543617 / 2020-001178-31: A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Active, not recruiting
3
760
Europe, Japan, US, RoW
Tiragolumab, MTIG7192A, RO7092284, Atezolizumab, Tecentriq, RO5541267, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo
Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
03/27
03/27
UmbrellaMAX, NCT05862285 / 2022-003414-36: A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Recruiting
3
60
Europe, Canada, Japan, RoW
Ipatasertib, RO5532961, Tiragolumab, RO7092284, Atezolizumab, RO5541276
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Cancer
03/33
03/33
A phase III, randomized, double-blind study of tiragolumab plus atezolizumab in adjuvant NSCLC, ChiCTR2400081195: A phase III, randomized, double-blind study of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with completely resected stage IIB, IIIA, or select IIIB, PD-L1 positive, non-small cell lung cancer who have received adjuvant platinum-based chemotherapy

Not yet recruiting
3
1150
 
Atezolizumab 1680 mg +Tiragolumab 840 mg; Atezolizumab 1680 mg +Tiragolumab Placebo 840 mg
Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences), Roche (China) Holding Ltd. , F. Hoffmann-La Roche Ltd
Non-small cell lung cancer
 
 
SKYSCRAPER-06, NCT04619797 / 2020-002851-39: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2025: Data from SKYSCRAPER-06 trial in combination with Tecentriq for advanced non squamous NSCLC
Active, not recruiting
2/3
542
Europe, Canada, Japan, US, RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
09/25
09/25
CITYSCAPE, NCT03563716 / 2018-000280-81: A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Checkmark Data from CITYSCAPE trial in combination with Tecentriq for NSCLC
Dec 2021 - Dec 2021: Data from CITYSCAPE trial in combination with Tecentriq for NSCLC
Checkmark 2.5 years median follow-up data from CITYSCAPE trial in combination with Tecentriq for IL NSCLC
Dec 2021 - Dec 2021: 2.5 years median follow-up data from CITYSCAPE trial in combination with Tecentriq for IL NSCLC
Checkmark Data from trial in combination with tiragolumab for advanced NSCLC at ESMO-2021
More
Active, not recruiting
2
135
Europe, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Placebo
Genentech, Inc.
Non-small Cell Lung Cancer
06/19
03/25
SKYSCRAPER-04, NCT04300647 / 2019-004895-21: A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Hourglass Jan 2023 - Jun 2023 : Data from SKYSCRAPER-04 trial in combination with tiragolumab for metastatic PD-L1+ cervical cancer
Completed
2
172
Europe, Canada, US, RoW
Tiragolumab, RO7092284, Atezolizumab, RO5541267, Tecentriq
Hoffmann-La Roche
Cervical Cancer
12/21
02/25
2020-002853-11: A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, with or Without Platinum-Based Chemotherapy, in Patients with Previously Untreated Locally Advanced Resectable Stage II, IIIa, or Select IIIb Non-Small Cell Lung Cancer.

Not yet recruiting
2
82
Europe
tiragolumab, RO7092284/F03-01, Concentrate for solution for infusion, Tecentriq
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Non-Small Cell Lung Cancer., Lung cancer that has spread to areas near the lungs or other organs and has not yet been treated by chemotherapy., Diseases [C] - Cancer [C04]
 
 
2021-005887-24: Tiraglolumab Atezolizumab and chemoradiotherapy in Localized Anal carcinoma (TIRANUS) Tiraglolumab Atezolizumab y quimio-radioterapia en carcinma localizado del Ano (TIRANUS)

Ongoing
2
45
Europe
Tiragolumab, Atezolizumab, Concentrate for solution for infusion, TECENTRIQ
Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD), ROCHE Ltd
Locallized squamous cell carcinoma of the anal canal in the first-line setting. Carcinoma epidermoide localizado del canal anal en primera línea., Carcinoma of the anal canal Carcinoma del canal anal, Diseases [C] - Cancer [C04]
 
 
2022-002265-15: A Study of RO7247669 Alone or in Combination with Tiragolumab Versus Atezolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer who are Ineligible for Platinum-Containing Chemotherapy

Ongoing
2
240
Europe
PD1-LAG3, tiragolumab, RO7247669/F01-01, RO5541267/F03-01, RO7092284/F03-01, Solution for infusion, Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Tecentriq®
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer, Urothelial Bladder Cancer is common type of cancer that has spread outside of the bladder to other parts of the body, this causes back pain, painful urination, frequent urination, and blood in urine., Diseases [C] - Cancer [C04]
 
 
2021-006430-39: A Study of Immune Checkpoint Inhibitor Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Un estudio de combinaciones inhibidoras de puntos de control inmunitario con Axitinib en pacientes con carcinoma de células renales no tratado previamente localmente avanzado no resectable o metastásico

Not yet recruiting
2
210
Europe
tiragolumab, PD1-LAG3, Pembrolizumab, RO7092284/F03-01, RO7247669/F01-01, RO7223188, Concentrate for solution for infusion, Solution for infusion, Film-coated tablet, INLYTA®, KEYTRUDA®
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd
Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Carcinoma de células renales localmente avanzado no resectable o carcinoma de células renales metastásico, Clear Cell Renal cell carcinoma (RCC), is the most common type of kidney cancer El carcinoma de células renales (CCR) de células claras es el tipo de cáncer de riñón más común, Diseases [C] - Cancer [C04]
 
 
2022-003708-33: A PHASE II STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RECURRENCE AND HIGH TUMOR MUTATIONAL BURDEN OR MICROSATELLITE INSTABILITY. ESTUDIO FASE II DE ATEZOLIZUMAB O ATEZOLIZUMAB EN COMBINACIÓN CON TIRAGOLUMAB COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON TUMORES SÓLIDOS RESECABLES CON RIESGO DE RECURRENCIA INTERMEDIO-ALTO Y ALTA CARGA MUTACIONAL TUMORAL O INESTABILIDAD DE MICROSATÉLITES

Not yet recruiting
2
40
Europe
Atezolizumab, tiragolumab, RO5541267, RO7092284/F03-01, Concentrate for solution for infusion, Tecentriq
Roche Farma S.A.U., Roche Farma S.A.U.
Solid tumors Tumores sólidos, Solid tumors are abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancerous), or malignant (cancerous) Los tumores sólidos son masas anormales de tejido que generalmente no contienen quistes o áreas líquidas. Los tumores sólidos pueden ser benignos (no cancerosos) o malignos (cancerosos), Diseases [C] - Cancer [C04]
 
 
NCT04308785: A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Terminated
2
24
RoW
Atezolizumab, Tecentriq, Tiragolumab, Placebo
Hoffmann-La Roche
Carcinoma, Small Cell Lung
07/23
07/23
SKYSCRAPER-09, NCT04665843 / 2020-002852-19: A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
2
123
Europe, US, RoW
Atezolizumab, Tecentriq, RO5541267, Tiragolumab, RO7092284, Placebo
Hoffmann-La Roche
Squamous Cell Carcinoma of Head and Neck
09/23
10/25
NCT04933227: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Terminated
2
29
RoW
Atezolizumab, Tecentriq, Tiragolumab, Oxaliplatin, Capecitabine
Hoffmann-La Roche
Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
11/23
11/23
NCT03977467: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Completed
2
46
US
Atezolizumab, TECENTRIQ, Chemotherapy (Arm A Only), Tiragolumab
SCRI Development Innovations, LLC, Genentech, Inc.
Non-Small Cell Lung Cancer, Solid Tumor
08/24
08/24
SKYROCKET, NCT05034055: Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer

Not yet recruiting
2
45
RoW
atezolizumab / tiragolumab
Yonsei University
Non-small Cell Lung Cancer
12/23
12/23
MyTACTIC, NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
2
252
US
Entrectinib, Rozlytrek™, RG6268, RO7102122, Inavolisib, GDC-0077, RG6114, RO7113755, Alectinib, Alecensa®, RG7853, RO5424802, Ipatasertib, GDC-0068, RG7440, RO5532961, Atezolizumab, Tecentriq®, RG7446, RO5541267, Trastuzumab Emtansine, Kadcyla®, RG3502, RO5304020, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574, Tucatinib, Tukysa™, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, RG6058, RO7092284, MTIG7192A, Pralsetinib, GAVRETO™, RG6396, RO7499790
Genentech, Inc.
Advanced Unresectable or Metastatic Solid Malignancy
12/23
02/24
NCT05009069: A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Active, not recruiting
2
58
RoW
Radiotherapy, Capecitabine, Fluorouracil, Atezolizumab, Tiragolumab
Hoffmann-La Roche
Rectal Neoplasms, Rectal Cancer
11/23
11/26
SKYLINE, NCT06175390: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

Recruiting
2
160
Europe
68Ga-FAPI-46 PET/CT, Tumor samples analysis, Blood samples analysis: Circulating Tumor DNA
Institut Curie, Hoffmann-La Roche
Triple Negative Breast Cancer
08/26
02/29
TONIC-3, NCT06342037: NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: Trial

Recruiting
2
60
Europe
Tiragolumab, Atezolizumab, Tecentriq, Ipilimumab, Yervoy
The Netherlands Cancer Institute, Hoffmann-La Roche
Metastatic Breast Cancer
04/26
04/30
NeoACTIVATE, NCT03554083: Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Active, not recruiting
2
59
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Tiragolumab, MTIG7192A, RG6058, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf
Mayo Clinic, National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
06/25
06/25
NCT04958811: Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Recruiting
2
42
US
Tiragolumab, Atezolizumab, Bevacizumab
Georgetown University, Genentech, Inc.
Non-squamous Non-small-cell Lung Cancer
12/25
12/25
NCT05805501 / 2021-006430-39: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Active, not recruiting
2
199
Europe, US, RoW
Tobemstomig, RO7247669, Tiragolumab, Pembrolizumab, Keytruda, Axitinib, Inlyta
Hoffmann-La Roche, F.Hoffmann-La Roche Ltd
Renal Cell Carcinoma
10/26
10/26
NCT05681039: Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients with Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Recruiting
2
29
US
Tiragolumab, Atezolizumab, MPDL3280A, TECENTRIQ, Standard of Care, Questionnaires, Cisplatin, Carboplatin
M.D. Anderson Cancer Center, Genentech, Inc.
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
11/25
11/26
IMperator, NCT06331598 / 2022-003708-33: A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Withdrawn
2
40
Europe
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A
Hoffmann-La Roche, Roche Farma S.A.U.
Solid Tumors
10/28
09/29
NCT03784326: Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Recruiting
2
40
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Conventional Surgery, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Tiragolumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
12/26
12/26
INDIGO, NCT06713798: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Not yet recruiting
2
115
Europe
Atezolizumab 1200 mg IV, Tiragolumab 600 mg IV
Gustave Roussy, Cancer Campus, Grand Paris, Roche Global Development
Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer
01/28
01/30
NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Terminated
2
7
US
Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay
Washington University School of Medicine, Genentech, Inc.
Stage II Melanoma
11/23
11/23
SKYSCRAPER-11, NCT05661578 / 2022-001157-23: A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Recruiting
2
60
Europe, Canada, US, RoW
Tiragolumab and Atezolizumab IV FDC
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
PD-L1-selected Solid Tumors
09/25
09/25
NCT06603818: Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Not yet recruiting
2
36
US
Tiragolumab, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
National Cancer Institute (NCI)
Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
12/26
06/27
NCT06328036: Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Withdrawn
2
52
NA
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery, Tiragolumab, MTIG7192A, RG6058
National Cancer Institute (NCI)
Recurrent Glioblastoma, IDH-Wildtype
07/25
07/25
NCT06784947: Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients with Microsatellite Stable, Metastatic Colorectal Cancer

Recruiting
2
54
US
Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab, Atezolizumab, Bevacizumab
University of Colorado, Denver, Genentech, Inc.
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
05/27
05/28
NCT06762808: Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Not yet recruiting
2
55
US
Atezolizumab, Talazoparib
M.D. Anderson Cancer Center, Genentech, Inc., Strategic Alliance
Squamous Cell Carcinoma
12/26
12/28
NCT06754501: A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Not yet recruiting
2
35
US
Atezolizumab, Tiragolumab
M.D. Anderson Cancer Center, Genentech, Inc., Strategic Alliance
Cancer
07/27
07/29
AFT-57, NCT05798663: Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Recruiting
2
178
US
Atezolizumab, Tecentriq, L01XC32, Tiragolumab
Alliance Foundation Trials, LLC., Genentech, Inc.
NSCLC
08/25
10/27
TIRACAN, NCT05483400: Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

Recruiting
2
97
Europe
Tiragolumab and atezolizumab
University Medical Center Groningen
Head and Neck Neoplasms, MSI-H Cancer, Melanoma
09/25
09/27
NCT05746481: Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Active, not recruiting
2
3
US
Tiragolumab, RO7092284, Atezolizumab, Tecentriq, RO5541267, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Liza Villaruz, MD, Genentech, Inc.
Non-small Cell Lung Cancer
08/24
08/26
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
NCT05715281: Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Recruiting
2
15
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Tiragolumab
National Cancer Institute (NCI)
Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
10/26
10/26
NCT05645692 / 2022-002265-15: A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Active, not recruiting
2
204
Europe, US, RoW
Atezolizumab, Tobemstomig, RO7247669, Tiragolumab
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Urothelial Cancer
12/26
12/26
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
NCT03708224: Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
55
US
Atezolizumab, Tecentriq, Tocilizumab, Actemra, Tiragolumab, anti-TIGIT
Alain Algazi, Genentech, Inc., American Head and Neck Society
Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
06/28
06/28
SKYSCRAPER-05, NCT04832854 / 2020-002853-11: A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2025: Data from SKYSCRAPER-05 trial for NSCLC
Completed
2
50
Europe, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Non-Small Cell Lung Cancer (NSCLC)
03/25
03/25
NCT05825625: NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Recruiting
2
35
Europe
Atezolizumab, Tecentriq, Tiragolumab, no other name available
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG
Non-small Cell Lung Cancer
11/29
02/30
2021-002147-29: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma) Un estudio que evalúa la eficacia y seguridad de múltiples combinaciones de tratamientos en pacientes con melanoma (morfeo-melanoma)

Not yet recruiting
1/2
336
Europe
Atezolizumab, PD1-LAG3, OPDIVO, tiragolumab, ipilimumab, RO5541267, RO7247669, RO7344269, RO7092284, Concentrate for solution for infusion, Tecentriq, OPDIVO®, YERVOY 5 mg/ml concentrate for solution for infusion
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Melanoma Melanoma, Melanoma is a form of skin cancer that begins in the cells (melanocytes) that control the pigment in your skin El melanoma es una forma de cáncer de piel que comienza en las células (melanocitos) que controlan el pigmento de la piel., Diseases [C] - Cancer [C04]
 
 
2021-005712-62: A Study to Evaluate the Efficacy and Safety of Multiple Treatment Combinations in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck

Not yet recruiting
1/2
180
Europe
tiragolumab, RO7092284, Concentrate for solution for infusion, Tecentriq, Carboplatin, Paclitaxel
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Squamous cell carcinoma of the head and neck, Squamous cell carcinoma of the head and neck occurs in the outermost surface of the skin or certain tissues within the head and neck region including the throat, mouth, sinuses and nose., Diseases [C] - Cancer [C04]
 
 
2021-001060-23: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination with Tiragolumab with or Without Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Not yet recruiting
1/2
118
Europe
Mosunetuzumab, Tocilizumab, Atezolizumab, Tiragolumab, RO7030816, RO4877533, RO5541267, RO7092284, Solution for injection, Concentrate for solution for infusion, RoActemra®, Tecentriq®
F. Hoffman-La Roche Ltd, F.Hoffman-La Roche Ltd
Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL), Non-Hodgkin Lymphoma is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes., Diseases [C] - Cancer [C04]
 
 
NCT05315713: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Terminated
1/2
8
Europe, Canada, US, RoW
Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab
Hoffmann-La Roche
Non-Hodgkin Lymphoma, Follicular Lymphoma
07/23
07/23
NCT05394337: Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Recruiting
1/2
10
US
Atezolizumab, MPDL3280A, TECENTRIQ, Tiragolumab
M.D. Anderson Cancer Center
Metastatic Malignancy
01/26
01/26
MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Active, not recruiting
1/2
410
Europe, US, RoW
5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284
Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
04/25
04/25
MORPHEUS mUC, NCT03869190 / 2017-004634-28: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Hourglass Jul 2020 - Dec 2020 : Initial safety and efficacy data from P1b/2 MORPHEUS trial for bladder cancer
Active, not recruiting
1/2
272
Europe, US, RoW
Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine
Hoffmann-La Roche, Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas
Urothelial Carcinoma, Bladder Cancer
10/24
05/26
NCT05251948: An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Active, not recruiting
1/2
40
RoW
Atezolizumab, Tecentriq, Capecitabine, Oxaliplatin, Tiragolumab
Hoffmann-La Roche
Gastric and Gastroesophageal Junction Carcinoma
06/25
12/25
NCT05116202 / 2021-002147-29: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Completed
1/2
110
Europe, US, RoW
Nivolumab, Ipilimumab, RO7247669 2100 mg, Atezolizumab, Tecentriq, RO5541267, Tiragolumab, RO7092284, RO7247669 600 mg
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Melanoma
09/23
05/24
NCT05908786: A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Recruiting
1/2
150
Europe, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Tiragolumab, Tobemstomig, RO7247669
Hoffmann-La Roche
Carcinoma, Hepatocellular
09/25
09/28
NCT05743504: Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients

Recruiting
1/2
32
RoW
Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin, Radiotherapy, Surgery
National Taiwan University Hospital
Locally Advanced Esophageal Squamous Cell Carcinoma
05/25
11/25
Morpheus Lung, NCT03337698 / 2017-001267-21: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Checkmark Combo atezolizumab
Nov 2017 - Nov 2017: Combo atezolizumab
Active, not recruiting
1/2
314
Europe, US, RoW
Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Zanzalintinib, Camonsertib
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
09/25
11/26
NCT05286801: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Recruiting
1/2
86
Canada, US, RoW
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Tiragolumab, MTIG7192A, RG6058, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
06/26
06/26
AFT-50 EndoMAP, NCT04486352: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting
1/2
148
US
Atezolizumab - 28 Day Cycle, Tecentriq, L01XC32, Bevacizumab, Avastin, L01XC07, Ipatasertib, RG7440, GDC-0068, Talazoparib, Talzenna, L01XX60, Trastuzumab emtansine, T-DM1, Kadcyla, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, GDC-0077, Letrozole, Femara, Giredestrant, GDC-9545, Abemaciclib, Verzenio
Alliance Foundation Trials, LLC., Genentech, Inc., Foundation Medicine, Pfizer, Eli Lilly and Company
Endometrial Cancer
10/25
10/26
MORPHEUS-PDAC, NCT03193190 / 2016-004126-42: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hourglass Feb 2024 - Jun 2024 : Results from MORPHEUS-PDAC trial in 1L mPDAC
Checkmark In combination with BL-8040 for pancreatic ductal adenocarcinoma
Dec 2019 - Dec 2019: In combination with BL-8040 for pancreatic ductal adenocarcinoma
Active, not recruiting
1/2
340
Europe, Japan, US, RoW
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Hoffmann-La Roche
Pancreatic Adenocarcinoma
02/25
02/25
Morpheus-Liver, NCT04524871 / 2020-001743-10: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers

Recruiting
1/2
518
Europe, US, RoW
Atezolizumab, Tecentriq, Bevacizumab 15 mg/kg, Avastin, Tiragolumab, Tocilizumab, Actemra, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg
Hoffmann-La Roche, Adagene Inc, Tempest Therapeutics, NiKang Therapeutics, Inc., Immune-Onc Therapeutics
Advanced Liver Cancers
12/26
12/26
NCT05459129 / 2021-005712-62: A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Completed
1/2
12
Europe, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, Carboplatin, Paclitaxel
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Squamous Cell Carcinoma of the Head and Neck
08/24
08/24
NCT04045028: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Terminated
1a/1b
41
US, RoW
Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab
Genentech, Inc.
Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
03/23
03/23
NEJ043, jRCT2080224926: Phase I study of Tiragolumab in patients with advanced solid tumors

Completed
1
6
Japan
tiragolumab (RG6058) - Roche, Tecentriq (atezolizumab) - Roche
Chugai Pharmaceutical Co., Ltd.
Advanced solid tumors
 
 
NCT04584112: A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed
1
83
Europe, US, RoW
Tiragolumab, Atezolizumab, Tecentriq, Nab-paclitaxel, Abraxane, Carboplatin, Doxorubicin, Lipodox, Doxil, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), filgrastim, pegfilgrastim, Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Hoffmann-La Roche
Triple-Negative Breast Cancer
03/23
03/23
GO30103, NCT02794571: Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed
1
518
Europe, Canada, Japan, US, RoW
Atezolizumab, MPDL3280A, RO5541267, Tecentriq, Tiragolumab, MTIG7192A, RO7092284, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
Genentech, Inc.
Advanced/Metastatic Tumors
11/24
11/24
IMMUNOs-SBRT, NCT05259319: Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan

Recruiting
1
92
Europe
Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ], Tiragolumab, Stereotactic body radiation therapy (SBRT)
Centre Georges Francois Leclerc
Metastatic Non Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Renal Cell Carcinoma, Metastatic Head and Neck Cancer
12/24
12/24
NCT06760481: Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Not yet recruiting
1
56
US
Tiragolumab, Atezolizumab, Radiation Therapy
M.D. Anderson Cancer Center
Advanced Solid Malignancies
09/28
09/30
Intrinsic, NCT04929223: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Recruiting
1
542
Europe, Canada, US, RoW
Inavolisib, Bevacizumab, Avastin, Cetuximab, Atezolizumab, Tecentriq, Tiragolumab, SY-5609, Divarasib, GDC-6036, FOLFOX, FOLFIRI
Hoffmann-La Roche
Metastatic Colorectal Cancer
08/27
11/28
renvistobart (BMS-986207) / BMS
2021-000039-29: Study of BMS-986207 in Combination with Nivolumab and Ipilimumab in Participants with Stage IV NSCLC

Not yet recruiting
2
240
Europe
BMS-986207, NIVOLUMAB - 10mL vial COMMERCIAL, IPILIMUMAB (200mg/40ml vial), IPILIMUMAB (50mg/10ml vial), BMS-986207, BMS-936558, BMS-734016, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Opdivo (100 mg/10 ml), YERVOY 5 mg/ml concentrate for solution for infusion
Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Small Cell Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NCT04065425: Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Not yet recruiting
1/2
104
NA
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3 Monoclonal Antibody BMS-986016, pomalidomide, dexamethasone, BMS-986016, Anti LAG-3, Relatlimab, Anti-TIGIT Monoclonal Antibody BMS-986207, pomalidomide, dexamethasone, BMS-986207, Anti TIGIT
Multiple Myeloma Research Consortium, Bristol-Myers Squibb
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
10/23
10/23
NCT04570839: COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Checkmark Data from a trial in combination with COM701 and BMS-986207 for platinum resistant ovarian cancer at ESMO-IO 2022
Dec 2022 - Dec 2022: Data from a trial in combination with COM701 and BMS-986207 for platinum resistant ovarian cancer at ESMO-IO 2022
Checkmark Data from trial in combination with opdivo for solid tumors at SITC 2021
Nov 2021 - Nov 2021: Data from trial in combination with opdivo for solid tumors at SITC 2021
Checkmark First patient dosed P1/2 study in the triple combination with Opdivo and BMS-986207 for solid tumor
More
Completed
1/2
48
US
COM701 in combination with BMS-986207 and nivolumab.
Compugen Ltd, Bristol-Myers Squibb
Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
05/24
05/24
NCT04150965: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Terminated
1/2
14
US
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3, BMS-986016, Anti LAG-3, Relatlimab, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-LAG-3, Pomalidomide, Dexamethasone, Anti-TIGIT, BMS-986207, Anti-TIGIT + Pomalidimide + Dexamethasone
Multiple Myeloma Research Consortium, Bristol-Myers Squibb, Emory University, Washington University School of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Texas, Hackensack Meridian Health, University of Michigan
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
08/24
08/24
NCT02913313: A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Completed
1/2
101
Europe, Canada, Japan, US, RoW
BMS-986207, Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Broad Solid Tumor
01/24
01/24
vibostolimab (MK-7684) / Merck (MSD)
2019-003956-35: Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 Refractory MEL

Not yet recruiting
1/2
200
Europe
PEMBROLIZUMAB, MK-1308 -process 2 drug product (25 mg/vial), Lenvatinib, MK-3475, MK-1308, E7080/MK-7902, MK-7684, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Melanoma, Melanoma, Diseases [C] - Cancer [C04]
 
 
2019-003978-22: Ph 1/2 Substudy of Neoadjuvant Oncological Treatment(s) in MEL Sottostudio di fase 1/2 sui trattamenti oncologici neoadiuvanti per il melanoma

Not yet recruiting
1/2
65
Europe
PEMBROLIZUMAB, -, CVA21, [MK-3475], [-], [MK-7684], [V937], Solution for infusion, Solution for injection, KEYTRUDA (pembrolizumab, MK-3475)
MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Melanoma Melanoma, Melanoma Melanoma, Diseases [C] - Cancer [C04]
 
 
2019-003977-24: Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL

Ongoing
1/2
510
Europe
PEMBROLIZUMAB, MK-3475, MK-7684, Solution for infusion, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck &, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Melanoma, Melanoma, Diseases [C] - Cancer [C04]
 
 
KEYMAKER-U02 Substudy 02C, NCT04303169: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Active, not recruiting
1/2
90
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Vibostolimab, MK-7684, Gebasaxturev, Coxsackievirus A21 (CVA21), Formerly known as CAVATAK®, CAV21, V937, MK-4830, Favezelimab + Pembrolizumab, MK-4280A, ATRA, Tretinoin, Vesanoid®
Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
KEYMAKER-U02 Substudy 02A, NCT04305041: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Active, not recruiting
1/2
200
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Quavonlimab, MK-1308, Vibostolimab, MK-7684, Lenvatinib, MK-7902, LENVIMA®, ATRA, VESANOID
Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
KEYMAKER-U02 Substudy 02B, NCT04305054 / 2019-003977-24: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Recruiting
1/2
315
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Vibostolimab, MK-7684, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA®, Favezelimab/Pembrolizumab, MK-4280A, ATRA
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck &, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
KEYMAKER-U01A, NCT04165070 / 2020-001626-56: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/)

Hourglass Jan 2022 - Dec 2022 : Of KEYNOTE-01A trial for advanced NSCLC
Recruiting
1/2
450
Europe, US, RoW
Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Carboplatin, PARAPLATIN®, Paclitaxel, ABRAXANE®, Pemetrexed, ALIMTA®, Vibostolimab, MK-7684, Boserolimab, MK-5890, MK-4830, MK-0482, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400, HER3-DXd, U3-1402, MK-1022
Merck Sharp & Dohme LLC, Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
02/39
02/39
KEYVIBE-001, NCT02964013: Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( )

Checkmark Data from part A of MK-7684-001 trial in combination with Keytruda for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from part A of MK-7684-001 trial in combination with Keytruda for NSCLC at ESMO 2020
Checkmark In combination with vibostolimab in advanced NSCLC at ESMO 2020
Sep 2020 - Sep 2020: In combination with vibostolimab in advanced NSCLC at ESMO 2020
Completed
1
470
NA
vibostolimab, MK-7684, pembrolizumab, KEYTRUDA®, MK-3475, pemetrexed, ALIMTA®, carboplatin, PARAPLATIN®, pembrolizumab/vibostolimab coformulation, MK-7684A, cisplatin, PLATINOL-AQ®, etoposide, ETOPOPHOS®
Merck Sharp & Dohme LLC
Neoplasms
07/24
07/24
etigilimab (MPH-313) / Mereo Biopharma
NCT05026606: Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
2
20
US
Etigilimab, Anti-TIGIT OMP-313M32, OMP 313M32, OMP-313M32, WHO 10742, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
M.D. Anderson Cancer Center
Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
12/23
12/23
NCT05715216: EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Recruiting
2
20
US
Nivolumab, BMS-936558, Opdivo, Etigilimab
M.D. Anderson Cancer Center, Mereo BioPharma
Ovarian Cancer
04/25
04/25
ACTIVATE, NCT04761198: A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

Hourglass May 2021 - Sep 2022 : Completion of enrollment of P1b/2 trial for solid tumors
Checkmark Presentation of data from ACTIVATE trial for solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from ACTIVATE trial for solid tumors at ESMO 2022
Checkmark Data from ACTIVATE trial in combination with Opdivo for solid tumors
Nov 2021 - Nov 2021: Data from ACTIVATE trial in combination with Opdivo for solid tumors
More
Completed
1/2
76
Europe, US
Etigilimab, MPH313, Nivolumab, Opdivo
Mereo BioPharma, ICON Clinical Research
Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
10/23
10/23
JS006 / Shanghai Junshi Biosci
NCT05061628: The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Recruiting
1
176
RoW
JS006 as Monotherapy, JS006 in combination with Toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Advanced Tumors
08/23
09/24
NCT05650203: A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Withdrawn
1
254
NA
JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006
Shanghai Junshi Bioscience Co., Ltd.
Primary Condition: Advanced Tumors
10/25
12/26
NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Terminated
1
22
US
CHS-006 (anti-TIGIT), JS006, toripalimab (anti-PD-1), CHS-007, TAB001, JS001
Coherus Biosciences, Inc., Medpace, Inc., Shanghai Junshi Bioscience Co., Ltd.
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
07/24
07/24
COM902 / Compugen
CPG-02-101, NCT04354246: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Checkmark Data from trial for solid tumors at SITC 2021
Nov 2021 - Nov 2021: Data from trial for solid tumors at SITC 2021
Checkmark First patient dosed in combination with COM701 in patients with advanced malignancies
Jul 2021 - Jul 2021: First patient dosed in combination with COM701 in patients with advanced malignancies
Recruiting
1
110
US
Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Compugen Ltd
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
12/24
03/25
belrestotug (EOS-448) / iTeos, GSK
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Completed
2
176
Europe, Canada, US, RoW
Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608
GlaxoSmithKline, iTeos Belgium SA
Neoplasms
05/24
05/24
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
2021-001329-29: A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors

Not yet recruiting
1/2
276
Europe
EOS-448, Inupadenant, Pembrolizumab, Inupadenant hydrochloride, Dostarlimab, EOS884448, EOS100850, L01XC18, EOS100850 HCl, Solution for infusion, Capsule, Keytruda® (pembrolizumab), Dostarlimab
iTeos Belgium SA, iTeos Belgium SA
Advanced solid tumors, Advanced solid Tumors, Diseases [C] - Cancer [C04]
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tiragolumab (RG6058) / Roche
SKYSCRAPER-02, NCT04256421 / 2019-003301-97: A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Checkmark From SKYSCRAPER-02 trial in combination with or without tiragolumab for ES SCLC
Mar 2022 - Mar 2022: From SKYSCRAPER-02 trial in combination with or without tiragolumab for ES SCLC
Active, not recruiting
3
490
Europe, Japan, US, RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Carboplatin, Etoposide, Placebo
Hoffmann-La Roche
Small Cell Lung Cancer
09/22
05/25
SKYSCRAPER-08, NCT04540211: A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

Jan 2023 - Dec 2023: Data from SKYSCRAPER-08 trial in combination with tiragolumab for metastatic esophageal carcinoma
Active, not recruiting
3
461
RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Paclitaxel, Cisplatin, Atezolizumab Matching Placebo, Tiragolumab Matching Placebo
Hoffmann-La Roche
Esophageal Cancer
02/23
01/26
SKYSCAPPER-02C, NCT04665856: Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Active, not recruiting
3
123
RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Carboplatin, Etoposide, Tiragolumab Matching Placebo
Hoffmann-La Roche
Small Cell Lung Carcinoma
08/23
12/25
SKYSCRAPER-15, NCT06267001: A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Active, not recruiting
3
56
Europe, Japan, RoW
Atezolizumab, Tecentriq; RO5541267, Tiragolumab, MTIG7192A; RO7092284, Placebo
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
12/25
12/25
SKYSCRAPER-03, NCT04513925 / 2019-004773-29: A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Calendar Jan 2025 - Dec 2025: From SKYSCRAPER-03 trial in combination with Tecentriq for unresectable stage 3 NSCLC
Active, not recruiting
3
829
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq; RO5541267, Tiragolumab, MTIG7192A; RO7092284, Durvalumab
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
08/25
12/27
SKYSCRAPER-01, NCT04294810 / 2019-002925-31: A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Jul 2023 - Sep 2023: Final analysis data from SKYSCRAPER-01 trial in combination with tiragolumab for NSCLC
Jan 2023 - Feb 2023: Interim data from SKYSCRAPER-01 trial in combination with tiragolumab for NSCLC
Checkmark Interim results from SKYSCRAPER-01 trial in combination with Tecentriq for 1L NSCLC
Jul 2022 - May 2022: Interim results from SKYSCRAPER-01 trial in combination with Tecentriq for 1L NSCLC
Active, not recruiting
3
620
Europe, Japan, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Matching Placebo
Hoffmann-La Roche
Non-Small Cell Lung Cancer
09/24
12/25
Imbrave 152, NCT05904886: A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Tiragolumab, MTIG7192A, Placebo
Hoffmann-La Roche, Chugai Pharmaceutical
Carcinoma, Hepatocellular
09/26
09/26
SKYSCRAPER-07, NCT04543617 / 2020-001178-31: A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Active, not recruiting
3
760
Europe, Japan, US, RoW
Tiragolumab, MTIG7192A, RO7092284, Atezolizumab, Tecentriq, RO5541267, Tiragolumab Matching Placebo, Atezolizumab Matching Placebo
Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
03/27
03/27
UmbrellaMAX, NCT05862285 / 2022-003414-36: A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Recruiting
3
60
Europe, Canada, Japan, RoW
Ipatasertib, RO5532961, Tiragolumab, RO7092284, Atezolizumab, RO5541276
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Cancer
03/33
03/33
A phase III, randomized, double-blind study of tiragolumab plus atezolizumab in adjuvant NSCLC, ChiCTR2400081195: A phase III, randomized, double-blind study of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with completely resected stage IIB, IIIA, or select IIIB, PD-L1 positive, non-small cell lung cancer who have received adjuvant platinum-based chemotherapy

Not yet recruiting
3
1150
 
Atezolizumab 1680 mg +Tiragolumab 840 mg; Atezolizumab 1680 mg +Tiragolumab Placebo 840 mg
Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences), Roche (China) Holding Ltd. , F. Hoffmann-La Roche Ltd
Non-small cell lung cancer
 
 
SKYSCRAPER-06, NCT04619797 / 2020-002851-39: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2025: Data from SKYSCRAPER-06 trial in combination with Tecentriq for advanced non squamous NSCLC
Active, not recruiting
2/3
542
Europe, Canada, Japan, US, RoW
Tiragolumab, MTIG7192A, Atezolizumab, Tecentriq, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
09/25
09/25
CITYSCAPE, NCT03563716 / 2018-000280-81: A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Checkmark Data from CITYSCAPE trial in combination with Tecentriq for NSCLC
Dec 2021 - Dec 2021: Data from CITYSCAPE trial in combination with Tecentriq for NSCLC
Checkmark 2.5 years median follow-up data from CITYSCAPE trial in combination with Tecentriq for IL NSCLC
Dec 2021 - Dec 2021: 2.5 years median follow-up data from CITYSCAPE trial in combination with Tecentriq for IL NSCLC
Checkmark Data from trial in combination with tiragolumab for advanced NSCLC at ESMO-2021
More
Active, not recruiting
2
135
Europe, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Placebo
Genentech, Inc.
Non-small Cell Lung Cancer
06/19
03/25
SKYSCRAPER-04, NCT04300647 / 2019-004895-21: A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Hourglass Jan 2023 - Jun 2023 : Data from SKYSCRAPER-04 trial in combination with tiragolumab for metastatic PD-L1+ cervical cancer
Completed
2
172
Europe, Canada, US, RoW
Tiragolumab, RO7092284, Atezolizumab, RO5541267, Tecentriq
Hoffmann-La Roche
Cervical Cancer
12/21
02/25
2020-002853-11: A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, with or Without Platinum-Based Chemotherapy, in Patients with Previously Untreated Locally Advanced Resectable Stage II, IIIa, or Select IIIb Non-Small Cell Lung Cancer.

Not yet recruiting
2
82
Europe
tiragolumab, RO7092284/F03-01, Concentrate for solution for infusion, Tecentriq
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Non-Small Cell Lung Cancer., Lung cancer that has spread to areas near the lungs or other organs and has not yet been treated by chemotherapy., Diseases [C] - Cancer [C04]
 
 
2021-005887-24: Tiraglolumab Atezolizumab and chemoradiotherapy in Localized Anal carcinoma (TIRANUS) Tiraglolumab Atezolizumab y quimio-radioterapia en carcinma localizado del Ano (TIRANUS)

Ongoing
2
45
Europe
Tiragolumab, Atezolizumab, Concentrate for solution for infusion, TECENTRIQ
Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD), ROCHE Ltd
Locallized squamous cell carcinoma of the anal canal in the first-line setting. Carcinoma epidermoide localizado del canal anal en primera línea., Carcinoma of the anal canal Carcinoma del canal anal, Diseases [C] - Cancer [C04]
 
 
2022-002265-15: A Study of RO7247669 Alone or in Combination with Tiragolumab Versus Atezolizumab in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer who are Ineligible for Platinum-Containing Chemotherapy

Ongoing
2
240
Europe
PD1-LAG3, tiragolumab, RO7247669/F01-01, RO5541267/F03-01, RO7092284/F03-01, Solution for infusion, Concentrate for solution for injection/infusion, Concentrate for solution for infusion, Tecentriq®
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Previously Untreated Locally Advanced or Metastatic Urothelial Bladder Cancer, Urothelial Bladder Cancer is common type of cancer that has spread outside of the bladder to other parts of the body, this causes back pain, painful urination, frequent urination, and blood in urine., Diseases [C] - Cancer [C04]
 
 
2021-006430-39: A Study of Immune Checkpoint Inhibitor Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Un estudio de combinaciones inhibidoras de puntos de control inmunitario con Axitinib en pacientes con carcinoma de células renales no tratado previamente localmente avanzado no resectable o metastásico

Not yet recruiting
2
210
Europe
tiragolumab, PD1-LAG3, Pembrolizumab, RO7092284/F03-01, RO7247669/F01-01, RO7223188, Concentrate for solution for infusion, Solution for infusion, Film-coated tablet, INLYTA®, KEYTRUDA®
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd
Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Carcinoma de células renales localmente avanzado no resectable o carcinoma de células renales metastásico, Clear Cell Renal cell carcinoma (RCC), is the most common type of kidney cancer El carcinoma de células renales (CCR) de células claras es el tipo de cáncer de riñón más común, Diseases [C] - Cancer [C04]
 
 
2022-003708-33: A PHASE II STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RECURRENCE AND HIGH TUMOR MUTATIONAL BURDEN OR MICROSATELLITE INSTABILITY. ESTUDIO FASE II DE ATEZOLIZUMAB O ATEZOLIZUMAB EN COMBINACIÓN CON TIRAGOLUMAB COMO TRATAMIENTO ADYUVANTE EN PACIENTES CON TUMORES SÓLIDOS RESECABLES CON RIESGO DE RECURRENCIA INTERMEDIO-ALTO Y ALTA CARGA MUTACIONAL TUMORAL O INESTABILIDAD DE MICROSATÉLITES

Not yet recruiting
2
40
Europe
Atezolizumab, tiragolumab, RO5541267, RO7092284/F03-01, Concentrate for solution for infusion, Tecentriq
Roche Farma S.A.U., Roche Farma S.A.U.
Solid tumors Tumores sólidos, Solid tumors are abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancerous), or malignant (cancerous) Los tumores sólidos son masas anormales de tejido que generalmente no contienen quistes o áreas líquidas. Los tumores sólidos pueden ser benignos (no cancerosos) o malignos (cancerosos), Diseases [C] - Cancer [C04]
 
 
NCT04308785: A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Terminated
2
24
RoW
Atezolizumab, Tecentriq, Tiragolumab, Placebo
Hoffmann-La Roche
Carcinoma, Small Cell Lung
07/23
07/23
SKYSCRAPER-09, NCT04665843 / 2020-002852-19: A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
2
123
Europe, US, RoW
Atezolizumab, Tecentriq, RO5541267, Tiragolumab, RO7092284, Placebo
Hoffmann-La Roche
Squamous Cell Carcinoma of Head and Neck
09/23
10/25
NCT04933227: A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Terminated
2
29
RoW
Atezolizumab, Tecentriq, Tiragolumab, Oxaliplatin, Capecitabine
Hoffmann-La Roche
Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
11/23
11/23
NCT03977467: Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Completed
2
46
US
Atezolizumab, TECENTRIQ, Chemotherapy (Arm A Only), Tiragolumab
SCRI Development Innovations, LLC, Genentech, Inc.
Non-Small Cell Lung Cancer, Solid Tumor
08/24
08/24
SKYROCKET, NCT05034055: Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer

Not yet recruiting
2
45
RoW
atezolizumab / tiragolumab
Yonsei University
Non-small Cell Lung Cancer
12/23
12/23
MyTACTIC, NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
2
252
US
Entrectinib, Rozlytrek™, RG6268, RO7102122, Inavolisib, GDC-0077, RG6114, RO7113755, Alectinib, Alecensa®, RG7853, RO5424802, Ipatasertib, GDC-0068, RG7440, RO5532961, Atezolizumab, Tecentriq®, RG7446, RO5541267, Trastuzumab Emtansine, Kadcyla®, RG3502, RO5304020, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574, Tucatinib, Tukysa™, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, RG6058, RO7092284, MTIG7192A, Pralsetinib, GAVRETO™, RG6396, RO7499790
Genentech, Inc.
Advanced Unresectable or Metastatic Solid Malignancy
12/23
02/24
NCT05009069: A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Active, not recruiting
2
58
RoW
Radiotherapy, Capecitabine, Fluorouracil, Atezolizumab, Tiragolumab
Hoffmann-La Roche
Rectal Neoplasms, Rectal Cancer
11/23
11/26
SKYLINE, NCT06175390: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

Recruiting
2
160
Europe
68Ga-FAPI-46 PET/CT, Tumor samples analysis, Blood samples analysis: Circulating Tumor DNA
Institut Curie, Hoffmann-La Roche
Triple Negative Breast Cancer
08/26
02/29
TONIC-3, NCT06342037: NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: Trial

Recruiting
2
60
Europe
Tiragolumab, Atezolizumab, Tecentriq, Ipilimumab, Yervoy
The Netherlands Cancer Institute, Hoffmann-La Roche
Metastatic Breast Cancer
04/26
04/30
NeoACTIVATE, NCT03554083: Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Active, not recruiting
2
59
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Tiragolumab, MTIG7192A, RG6058, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf
Mayo Clinic, National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
06/25
06/25
NCT04958811: Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Recruiting
2
42
US
Tiragolumab, Atezolizumab, Bevacizumab
Georgetown University, Genentech, Inc.
Non-squamous Non-small-cell Lung Cancer
12/25
12/25
NCT05805501 / 2021-006430-39: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Active, not recruiting
2
199
Europe, US, RoW
Tobemstomig, RO7247669, Tiragolumab, Pembrolizumab, Keytruda, Axitinib, Inlyta
Hoffmann-La Roche, F.Hoffmann-La Roche Ltd
Renal Cell Carcinoma
10/26
10/26
NCT05681039: Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients with Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Recruiting
2
29
US
Tiragolumab, Atezolizumab, MPDL3280A, TECENTRIQ, Standard of Care, Questionnaires, Cisplatin, Carboplatin
M.D. Anderson Cancer Center, Genentech, Inc.
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
11/25
11/26
IMperator, NCT06331598 / 2022-003708-33: A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Withdrawn
2
40
Europe
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A
Hoffmann-La Roche, Roche Farma S.A.U.
Solid Tumors
10/28
09/29
NCT03784326: Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Recruiting
2
40
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Conventional Surgery, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Tiragolumab
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
12/26
12/26
INDIGO, NCT06713798: Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Not yet recruiting
2
115
Europe
Atezolizumab 1200 mg IV, Tiragolumab 600 mg IV
Gustave Roussy, Cancer Campus, Grand Paris, Roche Global Development
Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer
01/28
01/30
NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Terminated
2
7
US
Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay
Washington University School of Medicine, Genentech, Inc.
Stage II Melanoma
11/23
11/23
SKYSCRAPER-11, NCT05661578 / 2022-001157-23: A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Recruiting
2
60
Europe, Canada, US, RoW
Tiragolumab and Atezolizumab IV FDC
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
PD-L1-selected Solid Tumors
09/25
09/25
NCT06603818: Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Not yet recruiting
2
36
US
Tiragolumab, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
National Cancer Institute (NCI)
Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
12/26
06/27
NCT06328036: Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Withdrawn
2
52
NA
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery, Tiragolumab, MTIG7192A, RG6058
National Cancer Institute (NCI)
Recurrent Glioblastoma, IDH-Wildtype
07/25
07/25
NCT06784947: Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients with Microsatellite Stable, Metastatic Colorectal Cancer

Recruiting
2
54
US
Pre-Treatment Biopsy, On-Treatment Biopsy, Tiragolumab, Atezolizumab, Bevacizumab
University of Colorado, Denver, Genentech, Inc.
Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV
05/27
05/28
NCT06762808: Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Not yet recruiting
2
55
US
Atezolizumab, Talazoparib
M.D. Anderson Cancer Center, Genentech, Inc., Strategic Alliance
Squamous Cell Carcinoma
12/26
12/28
NCT06754501: A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Not yet recruiting
2
35
US
Atezolizumab, Tiragolumab
M.D. Anderson Cancer Center, Genentech, Inc., Strategic Alliance
Cancer
07/27
07/29
AFT-57, NCT05798663: Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Recruiting
2
178
US
Atezolizumab, Tecentriq, L01XC32, Tiragolumab
Alliance Foundation Trials, LLC., Genentech, Inc.
NSCLC
08/25
10/27
TIRACAN, NCT05483400: Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

Recruiting
2
97
Europe
Tiragolumab and atezolizumab
University Medical Center Groningen
Head and Neck Neoplasms, MSI-H Cancer, Melanoma
09/25
09/27
NCT05746481: Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Active, not recruiting
2
3
US
Tiragolumab, RO7092284, Atezolizumab, Tecentriq, RO5541267, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Liza Villaruz, MD, Genentech, Inc.
Non-small Cell Lung Cancer
08/24
08/26
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
NCT05715281: Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Recruiting
2
15
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Tiragolumab
National Cancer Institute (NCI)
Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
10/26
10/26
NCT05645692 / 2022-002265-15: A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Active, not recruiting
2
204
Europe, US, RoW
Atezolizumab, Tobemstomig, RO7247669, Tiragolumab
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Urothelial Cancer
12/26
12/26
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
NCT03708224: Preoperative Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
55
US
Atezolizumab, Tecentriq, Tocilizumab, Actemra, Tiragolumab, anti-TIGIT
Alain Algazi, Genentech, Inc., American Head and Neck Society
Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
06/28
06/28
SKYSCRAPER-05, NCT04832854 / 2020-002853-11: A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2025: Data from SKYSCRAPER-05 trial for NSCLC
Completed
2
50
Europe, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Non-Small Cell Lung Cancer (NSCLC)
03/25
03/25
NCT05825625: NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Recruiting
2
35
Europe
Atezolizumab, Tecentriq, Tiragolumab, no other name available
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG
Non-small Cell Lung Cancer
11/29
02/30
2021-002147-29: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma) Un estudio que evalúa la eficacia y seguridad de múltiples combinaciones de tratamientos en pacientes con melanoma (morfeo-melanoma)

Not yet recruiting
1/2
336
Europe
Atezolizumab, PD1-LAG3, OPDIVO, tiragolumab, ipilimumab, RO5541267, RO7247669, RO7344269, RO7092284, Concentrate for solution for infusion, Tecentriq, OPDIVO®, YERVOY 5 mg/ml concentrate for solution for infusion
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Melanoma Melanoma, Melanoma is a form of skin cancer that begins in the cells (melanocytes) that control the pigment in your skin El melanoma es una forma de cáncer de piel que comienza en las células (melanocitos) que controlan el pigmento de la piel., Diseases [C] - Cancer [C04]
 
 
2021-005712-62: A Study to Evaluate the Efficacy and Safety of Multiple Treatment Combinations in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck

Not yet recruiting
1/2
180
Europe
tiragolumab, RO7092284, Concentrate for solution for infusion, Tecentriq, Carboplatin, Paclitaxel
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Squamous cell carcinoma of the head and neck, Squamous cell carcinoma of the head and neck occurs in the outermost surface of the skin or certain tissues within the head and neck region including the throat, mouth, sinuses and nose., Diseases [C] - Cancer [C04]
 
 
2021-001060-23: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination with Tiragolumab with or Without Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Not yet recruiting
1/2
118
Europe
Mosunetuzumab, Tocilizumab, Atezolizumab, Tiragolumab, RO7030816, RO4877533, RO5541267, RO7092284, Solution for injection, Concentrate for solution for infusion, RoActemra®, Tecentriq®
F. Hoffman-La Roche Ltd, F.Hoffman-La Roche Ltd
Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL), Non-Hodgkin Lymphoma is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes., Diseases [C] - Cancer [C04]
 
 
NCT05315713: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Terminated
1/2
8
Europe, Canada, US, RoW
Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab
Hoffmann-La Roche
Non-Hodgkin Lymphoma, Follicular Lymphoma
07/23
07/23
NCT05394337: Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Recruiting
1/2
10
US
Atezolizumab, MPDL3280A, TECENTRIQ, Tiragolumab
M.D. Anderson Cancer Center
Metastatic Malignancy
01/26
01/26
MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Active, not recruiting
1/2
410
Europe, US, RoW
5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284
Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
04/25
04/25
MORPHEUS mUC, NCT03869190 / 2017-004634-28: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Hourglass Jul 2020 - Dec 2020 : Initial safety and efficacy data from P1b/2 MORPHEUS trial for bladder cancer
Active, not recruiting
1/2
272
Europe, US, RoW
Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab, Sacituzumab Govitecan, Tocilizumab, Cisplatin, Gemcitabine
Hoffmann-La Roche, Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas
Urothelial Carcinoma, Bladder Cancer
10/24
05/26
NCT05251948: An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Active, not recruiting
1/2
40
RoW
Atezolizumab, Tecentriq, Capecitabine, Oxaliplatin, Tiragolumab
Hoffmann-La Roche
Gastric and Gastroesophageal Junction Carcinoma
06/25
12/25
NCT05116202 / 2021-002147-29: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Completed
1/2
110
Europe, US, RoW
Nivolumab, Ipilimumab, RO7247669 2100 mg, Atezolizumab, Tecentriq, RO5541267, Tiragolumab, RO7092284, RO7247669 600 mg
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Melanoma
09/23
05/24
NCT05908786: A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Recruiting
1/2
150
Europe, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Tiragolumab, Tobemstomig, RO7247669
Hoffmann-La Roche
Carcinoma, Hepatocellular
09/25
09/28
NCT05743504: Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients

Recruiting
1/2
32
RoW
Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin, Radiotherapy, Surgery
National Taiwan University Hospital
Locally Advanced Esophageal Squamous Cell Carcinoma
05/25
11/25
Morpheus Lung, NCT03337698 / 2017-001267-21: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Checkmark Combo atezolizumab
Nov 2017 - Nov 2017: Combo atezolizumab
Active, not recruiting
1/2
314
Europe, US, RoW
Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Zanzalintinib, Camonsertib
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
09/25
11/26
NCT05286801: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Recruiting
1/2
86
Canada, US, RoW
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Tiragolumab, MTIG7192A, RG6058, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
06/26
06/26
AFT-50 EndoMAP, NCT04486352: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting
1/2
148
US
Atezolizumab - 28 Day Cycle, Tecentriq, L01XC32, Bevacizumab, Avastin, L01XC07, Ipatasertib, RG7440, GDC-0068, Talazoparib, Talzenna, L01XX60, Trastuzumab emtansine, T-DM1, Kadcyla, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, GDC-0077, Letrozole, Femara, Giredestrant, GDC-9545, Abemaciclib, Verzenio
Alliance Foundation Trials, LLC., Genentech, Inc., Foundation Medicine, Pfizer, Eli Lilly and Company
Endometrial Cancer
10/25
10/26
MORPHEUS-PDAC, NCT03193190 / 2016-004126-42: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hourglass Feb 2024 - Jun 2024 : Results from MORPHEUS-PDAC trial in 1L mPDAC
Checkmark In combination with BL-8040 for pancreatic ductal adenocarcinoma
Dec 2019 - Dec 2019: In combination with BL-8040 for pancreatic ductal adenocarcinoma
Active, not recruiting
1/2
340
Europe, Japan, US, RoW
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Hoffmann-La Roche
Pancreatic Adenocarcinoma
02/25
02/25
Morpheus-Liver, NCT04524871 / 2020-001743-10: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers

Recruiting
1/2
518
Europe, US, RoW
Atezolizumab, Tecentriq, Bevacizumab 15 mg/kg, Avastin, Tiragolumab, Tocilizumab, Actemra, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg
Hoffmann-La Roche, Adagene Inc, Tempest Therapeutics, NiKang Therapeutics, Inc., Immune-Onc Therapeutics
Advanced Liver Cancers
12/26
12/26
NCT05459129 / 2021-005712-62: A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Completed
1/2
12
Europe, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, Carboplatin, Paclitaxel
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Squamous Cell Carcinoma of the Head and Neck
08/24
08/24
NCT04045028: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Terminated
1a/1b
41
US, RoW
Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab
Genentech, Inc.
Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
03/23
03/23
NEJ043, jRCT2080224926: Phase I study of Tiragolumab in patients with advanced solid tumors

Completed
1
6
Japan
tiragolumab (RG6058) - Roche, Tecentriq (atezolizumab) - Roche
Chugai Pharmaceutical Co., Ltd.
Advanced solid tumors
 
 
NCT04584112: A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed
1
83
Europe, US, RoW
Tiragolumab, Atezolizumab, Tecentriq, Nab-paclitaxel, Abraxane, Carboplatin, Doxorubicin, Lipodox, Doxil, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), filgrastim, pegfilgrastim, Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Hoffmann-La Roche
Triple-Negative Breast Cancer
03/23
03/23
GO30103, NCT02794571: Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed
1
518
Europe, Canada, Japan, US, RoW
Atezolizumab, MPDL3280A, RO5541267, Tecentriq, Tiragolumab, MTIG7192A, RO7092284, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Etoposide, Capecitabine, Bevacizumab, Pembrolizumab
Genentech, Inc.
Advanced/Metastatic Tumors
11/24
11/24
IMMUNOs-SBRT, NCT05259319: Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan

Recruiting
1
92
Europe
Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ], Tiragolumab, Stereotactic body radiation therapy (SBRT)
Centre Georges Francois Leclerc
Metastatic Non Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Renal Cell Carcinoma, Metastatic Head and Neck Cancer
12/24
12/24
NCT06760481: Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Not yet recruiting
1
56
US
Tiragolumab, Atezolizumab, Radiation Therapy
M.D. Anderson Cancer Center
Advanced Solid Malignancies
09/28
09/30
Intrinsic, NCT04929223: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Recruiting
1
542
Europe, Canada, US, RoW
Inavolisib, Bevacizumab, Avastin, Cetuximab, Atezolizumab, Tecentriq, Tiragolumab, SY-5609, Divarasib, GDC-6036, FOLFOX, FOLFIRI
Hoffmann-La Roche
Metastatic Colorectal Cancer
08/27
11/28
renvistobart (BMS-986207) / BMS
2021-000039-29: Study of BMS-986207 in Combination with Nivolumab and Ipilimumab in Participants with Stage IV NSCLC

Not yet recruiting
2
240
Europe
BMS-986207, NIVOLUMAB - 10mL vial COMMERCIAL, IPILIMUMAB (200mg/40ml vial), IPILIMUMAB (50mg/10ml vial), BMS-986207, BMS-936558, BMS-734016, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Opdivo (100 mg/10 ml), YERVOY 5 mg/ml concentrate for solution for infusion
Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb International Corporation
Small Cell Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04]
 
 
NCT04065425: Phase I/II Assessment of Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Not yet recruiting
1/2
104
NA
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3 Monoclonal Antibody BMS-986016, pomalidomide, dexamethasone, BMS-986016, Anti LAG-3, Relatlimab, Anti-TIGIT Monoclonal Antibody BMS-986207, pomalidomide, dexamethasone, BMS-986207, Anti TIGIT
Multiple Myeloma Research Consortium, Bristol-Myers Squibb
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
10/23
10/23
NCT04570839: COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Checkmark Data from a trial in combination with COM701 and BMS-986207 for platinum resistant ovarian cancer at ESMO-IO 2022
Dec 2022 - Dec 2022: Data from a trial in combination with COM701 and BMS-986207 for platinum resistant ovarian cancer at ESMO-IO 2022
Checkmark Data from trial in combination with opdivo for solid tumors at SITC 2021
Nov 2021 - Nov 2021: Data from trial in combination with opdivo for solid tumors at SITC 2021
Checkmark First patient dosed P1/2 study in the triple combination with Opdivo and BMS-986207 for solid tumor
More
Completed
1/2
48
US
COM701 in combination with BMS-986207 and nivolumab.
Compugen Ltd, Bristol-Myers Squibb
Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
05/24
05/24
NCT04150965: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Terminated
1/2
14
US
Elotuzumab, pomalidomide, dexamethasone, Empliciti, Anti-LAG-3, BMS-986016, Anti LAG-3, Relatlimab, Anti-LAG-3 + Pomalidimide + Dexamethasone, Anti-LAG-3, Pomalidomide, Dexamethasone, Anti-TIGIT, BMS-986207, Anti-TIGIT + Pomalidimide + Dexamethasone
Multiple Myeloma Research Consortium, Bristol-Myers Squibb, Emory University, Washington University School of Medicine, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Wake Forest University Health Sciences, Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, University of Texas, Hackensack Meridian Health, University of Michigan
Multiple Myeloma, Relapsed Refractory Multiple Myeloma
08/24
08/24
NCT02913313: A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors

Completed
1/2
101
Europe, Canada, Japan, US, RoW
BMS-986207, Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Broad Solid Tumor
01/24
01/24
vibostolimab (MK-7684) / Merck (MSD)
2019-003956-35: Ph 1/2 Substudy of Oncological Treatment(s) in PD-1 Refractory MEL

Not yet recruiting
1/2
200
Europe
PEMBROLIZUMAB, MK-1308 -process 2 drug product (25 mg/vial), Lenvatinib, MK-3475, MK-1308, E7080/MK-7902, MK-7684, Solution for infusion, Capsule, hard, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Melanoma, Melanoma, Diseases [C] - Cancer [C04]
 
 
2019-003978-22: Ph 1/2 Substudy of Neoadjuvant Oncological Treatment(s) in MEL Sottostudio di fase 1/2 sui trattamenti oncologici neoadiuvanti per il melanoma

Not yet recruiting
1/2
65
Europe
PEMBROLIZUMAB, -, CVA21, [MK-3475], [-], [MK-7684], [V937], Solution for infusion, Solution for injection, KEYTRUDA (pembrolizumab, MK-3475)
MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Melanoma Melanoma, Melanoma Melanoma, Diseases [C] - Cancer [C04]
 
 
2019-003977-24: Ph 1/2 Substudy of 1L Oncological Treatment(s) in Advanced MEL

Ongoing
1/2
510
Europe
PEMBROLIZUMAB, MK-3475, MK-7684, Solution for infusion, KEYTRUDA (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck &, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Melanoma, Melanoma, Diseases [C] - Cancer [C04]
 
 
KEYMAKER-U02 Substudy 02C, NCT04303169: Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Active, not recruiting
1/2
90
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Vibostolimab, MK-7684, Gebasaxturev, Coxsackievirus A21 (CVA21), Formerly known as CAVATAK®, CAV21, V937, MK-4830, Favezelimab + Pembrolizumab, MK-4280A, ATRA, Tretinoin, Vesanoid®
Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
KEYMAKER-U02 Substudy 02A, NCT04305041: Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Active, not recruiting
1/2
200
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Quavonlimab, MK-1308, Vibostolimab, MK-7684, Lenvatinib, MK-7902, LENVIMA®, ATRA, VESANOID
Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
KEYMAKER-U02 Substudy 02B, NCT04305054 / 2019-003977-24: Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Recruiting
1/2
315
Europe, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Vibostolimab, MK-7684, Pembrolizumab/Quavonlimab, MK-1308A, Lenvatinib, MK-7902, E7080, LENVIMA®, Favezelimab/Pembrolizumab, MK-4280A, ATRA
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck &, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme LLC
Melanoma
04/30
04/30
KEYMAKER-U01A, NCT04165070 / 2020-001626-56: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/)

Hourglass Jan 2022 - Dec 2022 : Of KEYNOTE-01A trial for advanced NSCLC
Recruiting
1/2
450
Europe, US, RoW
Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Carboplatin, PARAPLATIN®, Paclitaxel, ABRAXANE®, Pemetrexed, ALIMTA®, Vibostolimab, MK-7684, Boserolimab, MK-5890, MK-4830, MK-0482, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400, HER3-DXd, U3-1402, MK-1022
Merck Sharp & Dohme LLC, Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
02/39
02/39
KEYVIBE-001, NCT02964013: Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( )

Checkmark Data from part A of MK-7684-001 trial in combination with Keytruda for NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from part A of MK-7684-001 trial in combination with Keytruda for NSCLC at ESMO 2020
Checkmark In combination with vibostolimab in advanced NSCLC at ESMO 2020
Sep 2020 - Sep 2020: In combination with vibostolimab in advanced NSCLC at ESMO 2020
Completed
1
470
NA
vibostolimab, MK-7684, pembrolizumab, KEYTRUDA®, MK-3475, pemetrexed, ALIMTA®, carboplatin, PARAPLATIN®, pembrolizumab/vibostolimab coformulation, MK-7684A, cisplatin, PLATINOL-AQ®, etoposide, ETOPOPHOS®
Merck Sharp & Dohme LLC
Neoplasms
07/24
07/24
etigilimab (MPH-313) / Mereo Biopharma
NCT05026606: Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
2
20
US
Etigilimab, Anti-TIGIT OMP-313M32, OMP 313M32, OMP-313M32, WHO 10742, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
M.D. Anderson Cancer Center
Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
12/23
12/23
NCT05715216: EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Recruiting
2
20
US
Nivolumab, BMS-936558, Opdivo, Etigilimab
M.D. Anderson Cancer Center, Mereo BioPharma
Ovarian Cancer
04/25
04/25
ACTIVATE, NCT04761198: A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

Hourglass May 2021 - Sep 2022 : Completion of enrollment of P1b/2 trial for solid tumors
Checkmark Presentation of data from ACTIVATE trial for solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from ACTIVATE trial for solid tumors at ESMO 2022
Checkmark Data from ACTIVATE trial in combination with Opdivo for solid tumors
Nov 2021 - Nov 2021: Data from ACTIVATE trial in combination with Opdivo for solid tumors
More
Completed
1/2
76
Europe, US
Etigilimab, MPH313, Nivolumab, Opdivo
Mereo BioPharma, ICON Clinical Research
Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
10/23
10/23
JS006 / Shanghai Junshi Biosci
NCT05061628: The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Recruiting
1
176
RoW
JS006 as Monotherapy, JS006 in combination with Toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Advanced Tumors
08/23
09/24
NCT05650203: A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Withdrawn
1
254
NA
JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006
Shanghai Junshi Bioscience Co., Ltd.
Primary Condition: Advanced Tumors
10/25
12/26
NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Terminated
1
22
US
CHS-006 (anti-TIGIT), JS006, toripalimab (anti-PD-1), CHS-007, TAB001, JS001
Coherus Biosciences, Inc., Medpace, Inc., Shanghai Junshi Bioscience Co., Ltd.
Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
07/24
07/24
COM902 / Compugen
CPG-02-101, NCT04354246: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Checkmark Data from trial for solid tumors at SITC 2021
Nov 2021 - Nov 2021: Data from trial for solid tumors at SITC 2021
Checkmark First patient dosed in combination with COM701 in patients with advanced malignancies
Jul 2021 - Jul 2021: First patient dosed in combination with COM701 in patients with advanced malignancies
Recruiting
1
110
US
Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Compugen Ltd
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
12/24
03/25
belrestotug (EOS-448) / iTeos, GSK
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Recruiting
3
1000
Europe, Canada, Japan, RoW
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
09/28
09/29
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Completed
2
176
Europe, Canada, US, RoW
Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608
GlaxoSmithKline, iTeos Belgium SA
Neoplasms
05/24
05/24
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
2021-001329-29: A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors

Not yet recruiting
1/2
276
Europe
EOS-448, Inupadenant, Pembrolizumab, Inupadenant hydrochloride, Dostarlimab, EOS884448, EOS100850, L01XC18, EOS100850 HCl, Solution for infusion, Capsule, Keytruda® (pembrolizumab), Dostarlimab
iTeos Belgium SA, iTeos Belgium SA
Advanced solid tumors, Advanced solid Tumors, Diseases [C] - Cancer [C04]
 
 
 

Download Options